Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Место гефитиниба (ИрессаТМ) в лечениинемелкоклеточного рака легкого:клинико-экономическое обоснование
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Alroy I, Yarden Y. The ErbB signalling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 1997; 410: 83–6.
2. Blackhall FH, Shepherd FA, Albain KS. Improving survival and reducing toxicity with chemotherapy in advanced non-small-cell lung cancer: a realistic goal? Treat Respir Med 2005; 4: 71–84.
3. Bunn PA Jr, Franklin W. Epidermal growth factor receptor expression, signal pathway and inhibitors in non-small cell lung cancer. Semin Oncol 2002; 29: 38–44.
4. Burgess AW, Cho HS, Eigenbrot С et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003; 12: 541–52.
5. Douillard J-Y, Kim E, Hirsch V et al. Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-smallcell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST). J Thorac Oncol 2007; 2 (8 Suppl. 4): S305 (PPS-02).
6. Felip E, Baselga J. Receptor kinase abnormalities. In: Lung Cancer: Principles and Practice (2nd ed.). Pass HI, Mitchell JB, Johnson DH, Turrisi AT III, Minna JD (eds). Lippincott, Williams and Wilkins, PA, USA, 2002.
7. Gorgoulis V, Aninos D, Mikou P et al. Expression of EGF, TGF-a and EGFR in squamous cell lung carcinomas. Anticancer Res 1992; 12: 1183–8.
8. Hanna N, Shepherd FA, Fosella FV et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589–97.
9. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998; 74: 49–39.
10. Massarelli E, Andre F, Liu DD et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-smallcell lung cancer. Lung Cancer 2003; 39: 55–61.
11. Novello S, Le Chevalier T. Chemotherapy for non-small-cell lung cancer. Part 1: early stage disease. Oncology 2003; 17: 357–64.
12. Olayioye MA, Neve RM, Lane HA et al. The ErbB signalling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19: 3159–67.
13. Pavelic K, Banjac Z, Pavelic J, Spaventi S. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 1993; 13: 1133–8.
14. Roskoski R Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004; 319: 1–11.
15. Rusch V, Baselga J, Cordon-Cardo С et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993; 53: 2379–85.
16. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with nonsmall-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18 (10): 2095–103.
17. Tateishi M, Ishida T, Mitsudomi T et al. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res 1990; 50: 7077–80.
18. Wakeling AE, Barker AJ, Davies DH et al. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res Treat 1996; 38 (1): 67–73.
19. Государственный реестр цен на лекарственные средства, относящиеся к перечню ЖНВЛС №25 от 04.05.2009 г. http://www.drugreg.ru/Bases.
20. Отраслевой стандарт «Клинико-экономические исследования. Общие положения» Приказ Минздрава РФ от 27.05.2002 №163 вместе с ОСТ 91500.14.0001-2002 http://www.healtheconomics.ru/index.php?option=com_content&view=article&id=300:-q-q&....
21. Прейскурант на оказание медицинских услуг, Московский областной онкологический диспансер, май 2009 г.
22. Прейскурант оказания медицинских услуг клиник ММА им. И.М.Сеченова от 01.04.2009 г. www.mma.ru/clinicalcenter/medserv.
23. Сайт «Бюллетеня оптовых предложений лекарств» от 6 мая 2009 г. http://www.pharmindex.ru.
24. Тарифы на проезд в общественном транспорте на 2008 год, г. Москва. http://netall.ru/gnn/index.php?SECTION_ID=575&ID=230449.
2. Blackhall FH, Shepherd FA, Albain KS. Improving survival and reducing toxicity with chemotherapy in advanced non-small-cell lung cancer: a realistic goal? Treat Respir Med 2005; 4: 71–84.
3. Bunn PA Jr, Franklin W. Epidermal growth factor receptor expression, signal pathway and inhibitors in non-small cell lung cancer. Semin Oncol 2002; 29: 38–44.
4. Burgess AW, Cho HS, Eigenbrot С et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003; 12: 541–52.
5. Douillard J-Y, Kim E, Hirsch V et al. Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-smallcell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST). J Thorac Oncol 2007; 2 (8 Suppl. 4): S305 (PPS-02).
6. Felip E, Baselga J. Receptor kinase abnormalities. In: Lung Cancer: Principles and Practice (2nd ed.). Pass HI, Mitchell JB, Johnson DH, Turrisi AT III, Minna JD (eds). Lippincott, Williams and Wilkins, PA, USA, 2002.
7. Gorgoulis V, Aninos D, Mikou P et al. Expression of EGF, TGF-a and EGFR in squamous cell lung carcinomas. Anticancer Res 1992; 12: 1183–8.
8. Hanna N, Shepherd FA, Fosella FV et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589–97.
9. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998; 74: 49–39.
10. Massarelli E, Andre F, Liu DD et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-smallcell lung cancer. Lung Cancer 2003; 39: 55–61.
11. Novello S, Le Chevalier T. Chemotherapy for non-small-cell lung cancer. Part 1: early stage disease. Oncology 2003; 17: 357–64.
12. Olayioye MA, Neve RM, Lane HA et al. The ErbB signalling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19: 3159–67.
13. Pavelic K, Banjac Z, Pavelic J, Spaventi S. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 1993; 13: 1133–8.
14. Roskoski R Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004; 319: 1–11.
15. Rusch V, Baselga J, Cordon-Cardo С et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993; 53: 2379–85.
16. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with nonsmall-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18 (10): 2095–103.
17. Tateishi M, Ishida T, Mitsudomi T et al. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res 1990; 50: 7077–80.
18. Wakeling AE, Barker AJ, Davies DH et al. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res Treat 1996; 38 (1): 67–73.
19. Государственный реестр цен на лекарственные средства, относящиеся к перечню ЖНВЛС №25 от 04.05.2009 г. http://www.drugreg.ru/Bases.
20. Отраслевой стандарт «Клинико-экономические исследования. Общие положения» Приказ Минздрава РФ от 27.05.2002 №163 вместе с ОСТ 91500.14.0001-2002 http://www.healtheconomics.ru/index.php?option=com_content&view=article&id=300:-q-q&....
21. Прейскурант на оказание медицинских услуг, Московский областной онкологический диспансер, май 2009 г.
22. Прейскурант оказания медицинских услуг клиник ММА им. И.М.Сеченова от 01.04.2009 г. www.mma.ru/clinicalcenter/medserv.
23. Сайт «Бюллетеня оптовых предложений лекарств» от 6 мая 2009 г. http://www.pharmindex.ru.
24. Тарифы на проезд в общественном транспорте на 2008 год, г. Москва. http://netall.ru/gnn/index.php?SECTION_ID=575&ID=230449.
Авторы
Ю.Б.Белоусов, М.М.Константинова, Д.Ю.Белоусов
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.